SER · Serina Therapeutics, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on SER. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About SER · Serina Therapeutics, Inc.
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.
Live Quote
SELL (score -3) · 12-1 mom -66.8% · RSI 52.1 · above_50_only · -68.9% from high
Targets blend Wall Street consensus (1 analysts: low $11.00 / mean $11.00 / high $11.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
After thorough investigation of SER — triggered by the [insider_cluster_universe] flag for 4 Form 4 filings in last 14 days with verified open-market P/S trades — I found that none of those 4 recent Form 4 filings represent genuine open-market stock purchases. All four May-26 filed transactions (CEO, CFO, CSO, SVP) are grants of company-issued stock options (code A = acquisition from issuer, $1.89 exercise price). The actual open-market insider activity in the past 90 days is limited to one Form 4 showing Randall Moreadith exercising old deeply-vested options ($0.06 strike) and immediately selling shares at $2.50-$2.86 — a routine liquidation with no directional signal about current intrinsic value. This is not a smart-money cluster. On the fundamentals: pre-revenue biotech with ~$24.5M cash, burning ~$4-6M/quarter in opex, Phase 1b trial for lead asset SER-252 underway with topline SAD data expected H1 2027 (18+ months away). No options market exists (expiries list is empty). The stock is down ~76% from its March 2025 peak of $7.92 and technically broken. The thesis has no near-term catalyst, no smart money accumulation confirmed, and limited data edge.
Lessons Referencing This Ticker
For pre-revenue mining companies, the key earnings catalyst is operational progress (mine start-up, production targets, permitting status), not EPS. EPS misses are expected and priced in. Market reaction is driven by whether operational milestones are met or delayed, not financial performance. Score catalysts based on operational milestone significance, not EPS surprise potential.
extracted Jun 19, 2026 from 2026-06-01-UEC-earnings-put-spread
In cybersecurity names during AI-capex peaks, executive sales (even Rule 10b5-1) at prices significantly below current spot should be weighted more heavily than analyst upgrades. Insiders are closer to the data and may be positioning for a plateau.
extracted Jun 19, 2026 from 2026-06-01-PANW-earnings-debit-call